Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: Implications for MDR-TB treatment and the definition of XDR-TB

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 333-338

  Niward, Katarina ^a,b   Ängeby, Kristian ^c,d   Chryssanthou, Erja ^c,e   Paues, Jakob ^a,b   Bruchfeld, Judith ^c,e   Jureen, Pontus ^f   Giske, Christian G ^c,e   Kahlmeter, Gunnar ^g,h   Schön, Thomas ^b,i  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF THE WEST INDIES   (Jamaica)

^e KAROLINSKA INSTITUTE   (Sweden)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

^h Vaxjo Hospital   (Sweden)

ⁱ KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; SENSITIVITY AND SPECIFICITY; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MISSENSE MUTATION; NOMENCLATURE;

ANTITUBERCULAR AGENTS; DNA GYRASE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TERMINOLOGY AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84959931100     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv353     Document Type: Article

References (22)

1. Organization WH. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization, 2014. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=1.
2. Maruri F, Sterling TR, Kaiga AW. et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67: 819-31.
3. Avalos E, Catanzaro D, Catanzaro A et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One 2015; 10: e0120470.
4. Chang KC, Yew WW, Chan RC. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2010; 65: 1551-61.
5. Schön T, Jureen P, Giske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-93.
6. Angeby KA, Jureen P, Giske CG et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010; 65: 946-52.
7. Angeby K, Jureen P, Kahlmeter G et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012; 90: 693-8.
8. Kahlmeter G. Defining antibiotic resistance-towards international harmonization. Ups J Med Sci 2014; 119: 78-86.
9. Sturegard E, Angeby KA, Werngren J et al. Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10. Clin Microbiol Chemother 2015; 21: 148 e5-7.
10. Jureen P, Werngren J, Hoffner SE. Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2004; 84: 311-6.
11. Rosales-Klintz S, Jureen P, Zaluskaya A, Skrahina A, Xu B, Hu Y, Pineda-Gracia L, Aghali Merza M, Muntean I, Bwanga F, Joloba M, Hoffner SE. Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions. Int J Mycobacteriol 2012; 1: 124-30.
12. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-12.
13. Organization WHO. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. 1998; WHO/HTM/TB/2008.392. http://www.who.int/tb/publications/2008/whohtmtb_2008_392/en/.
14. Sun Z, Zhang J, Zhang X et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008; 31: 115-21.
15. Shi R, Zhang J, Li C et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006; 44: 4566-8.
16. Sirgel FA, Warren RM, Streicher EM et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-93.
17. Chang KC, Yew WW, Tam CM et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-104.
18. Bastos ML, Hussain H, Weyer K et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-74.
19. Ahuja SD, Ashkin D, Avendano M et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012; 9: e1001300.
20. Peloquin CA, Hadad DJ, Molino LP et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-7.
21. Zvada SP, Denti P, Sirgel FA et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob Agents Chemother 2014; 58: 503-10.
22. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-54.